Eli Lilly's weight-loss drug Zepbound has shown promise in treating moderate to severe obstructive sleep apnea, according to data from two late-stage trials. The trials revealed that Zepbound helped resolve sleep apnea in up to 52% of patients. Consequently, Eli Lilly has applied for FDA approval to expand the drug's use to include sleep apnea treatment and expects a decision by the end of the year. The company also plans to seek global regulatory approvals. The positive trial results have led to a selloff in sleep apnea device stocks, including ResMed, whose shares fell as investors anticipate a shift in treatment methods. Experts are divided on whether Zepbound will significantly impact the sales of CPAP machines, which are currently a primary treatment for sleep apnea.
Eli Lilly's Zepbound could become the first drug on the market to treat sleep apnea. What does that mean for the future of CPAP machines? https://t.co/bu00NwK6HH
Turns out losing weight fixes most health issues! Eli Lilly & Co $LLY $NVO: The company said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials. Patients in the first study received…
Experts split on whether Eli Lilly’s Zepbound will hamper CPAP sales https://t.co/rpUM2b2Cjb via @statnews
Experts split on whether Eli Lilly’s Zepbound will hamper CPAP sales https://t.co/u2LLR14XZR via @LizzyLaw_ and @elaineywchen for @statnews
Lilly's Zepbound worked in sleep apnea patients - how will that impact CPAP and other device makers? @elaineywchen and I asked the experts: https://t.co/c3wAetiv8J
After showing positive Phase 3 data in sleep apnea — will Lilly's Zepbound hamper CPAP sales? Experts are divided. w/ @LizzyLaw_ https://t.co/F0aJ5gY5ut
Eli Lilly’s Zepbound reduced sleep apnea symptoms, in a meaningful way according to new data. @LizzyLaw_ and @elaineywchen looked into that could mean for CPAP machines, which sleep apnea patients have come to rely on. https://t.co/w5pq52MNnt via @statnews
Eli Lilly weight-loss drug data causes drop in sleep apnea treatment stocks https://t.co/eGQzmKEafM
The future of CPAP machines is being debated in the wake of impressive Eli Lilly Zepbound trial results for treating sleep apnea, and device makers' stocks sank on the news. https://t.co/YMrTYNgGe5
Lilly weight-loss drug data spurs selloff in sleep apnea stocks https://t.co/xFv4j8uRAb
Medical-device makers ResMed and Inspire slump after Lilly’s Zepbound trial shows benefits for sleep apnea https://t.co/yo4LevBnMq
Lilly weight-loss drug data spurs selloff in sleep apnea stocks https://t.co/m2NfWWzdVm via @business
"Breakthrough" Eli Lilly Weight-Loss Drug Data To Treat Obesity & Sleep Apnea, Sends CPAP Device-Makers Plunging https://t.co/MpKpoD17Mp
Amid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod https://t.co/gODAWPm8bG
Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data https://t.co/epLV00NeqQ $LLY $ALT $VRTX $AMLX $NVO
ResMed Stock Is Sinking. Blame Lilly’s Zepbound Trials for Sleep Apnea. https://t.co/n594cER7QD
ResMed $RMD shares fell as Eli Lilly's $LLY weight-loss drug Zepbound shows promise in resolving moderate to severe obstructive sleep apnea in up to 52% of patients in late-stage trials. Lilly has submitted an FDA application and plans to seek global regulatory approvals soon.
Popular weight loss drug may help treat severe sleep apnea, new research finds | NBC News Drugmaker Eli Lilly and Co., who paid for the research, has asked the FDA to expand use of the weekly medication to treat moderate to severe sleep apnea A popular obesity drug may help… https://t.co/1jwxDu0Gjk
Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of sleep apnea and expects regulators to make a decision as early as the end of the year. https://t.co/di9nwTSQvq
The company released additional data from two late-stage trials showing that Zepbound helped resolve obstructive sleep apnea in almost half of patients. https://t.co/KLZhDPlcGQ
the American Eater Wins Again Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year https://t.co/BYEeD7IyLK
Eli Lilly seeks FDA’s OK to expand Zepbound’s uses to include sleep apnea
#Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
Eli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials. https://t.co/xyxbapDX7T https://t.co/xyxbapDX7T
A popular weight loss drug may be able to assist in the treatment of sleep apnea, a new study found. Here's what we know: https://t.co/xP55LvG7ZJ